Cited by 248Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease

Drzezga, A., Grimmer, T., Henriksen, G., Mühlau, M., Perneczky, R., Miederer, I., Praus, C., Sorg, C., Wohlschläger, A., Riemenschneider, M., Wester, H. J., Foerstl, H., Schwaiger, M., Kurz, A.·2009·Neurology

DOI 10.1212/wnl.0b013e3181a2e8d0

Open this paper in CoChat — free account

Abstract

OBJECTIVE: To examine the influence of the APOE genotype on levels of beta-amyloid (Abeta) plaque load and atrophy in patients with Alzheimer disease (AD) in vivo. METHODS: Thirty-two patients with moderate AD were divided into carriers and noncarriers of the epsilon4 allele. These groups were matched for age, disease duration, education, and cognitive impairment. In all subjects, [11C]PIB-PET was performed for measurement of cerebral Abeta plaque deposition and cranial MRI for the assessment of gray matter volume by voxel-based morphometry (VBM) and for correction of partial volume effects (PVE) in the PET data. Voxel-based comparisons (SPM5) were performed between patient groups and healthy control populations and completed with multiple regression analyses between imaging data and epsilon4 allele frequency. RESULTS: Compared to controls, AD-typical patterns of [11C]PIB retention and atrophy were detected in both epsilon4-positive and epsilon4-negative patient groups. In direct comparison, significantly stronger and more extended [11C]PIB uptake was found in epsilon4-positive patients in bilateral temporoparietal and frontal cortex, surviving PVE correction. VBM analysis demonstrated comparable levels of atrophy in both patient groups. Regression analyses revealed a linear association between higher epsilon4 allele frequency and stronger temporoparietal Abeta plaque deposition, independently of other confounds. No major correlation between epsilon4 allele frequency and gray matter decrease was observed. CONCLUSION: These results indicate that the epsilon4-positive APOE genotype not only represents a risk factor for Alzheimer disease (AD), but also results in higher levels of Abeta plaque deposition in epsilon4-positive patients with AD compared to age-matched epsilon4-negative patients with similar levels of cognitive impairment and brain atrophy. The potential role of Abeta plaque imaging for patient inclusion and follow-up in anti-amyloid therapy trials is strengthened by these findings.

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e3181a2e8d0

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Thresholding of statistical maps in functional neuroimaging using the false discovery rate
Genovese, C. R., Lazar, N. A., & Nichols, T. (2002) · NeuroImage · doi:10.1006/nimg.2001.1037 · Cited by 4,923
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment
Jack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958
In Vivo Mapping of Gray Matter Loss with Voxel-Based Morphometry in Mild Alzheimer's Disease
Baron, J., Chételat, G., Desgranges, B., Perchey, G., Landeau, B., Sayette, V. D. L., & Eustache, F. (2001) · NeuroImage · doi:10.1006/nimg.2001.0848 · Cited by 699
Clinicopathologic Studies in Cognitively Healthy Aging and Alzheimer Disease: Relation of Histologic Markers to Dementia Severity, Age, Sex, and Apolipoprotein E Genotype
Berg, L., McKeel, D. W., Miller, J. P., Storandt, M., Rubin, E. H., Morris, J. C., Baty, J., Coats, M., Norton, J., Goate, A. M., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.326 · Cited by 657
Apolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein
Polvikoski, T., Sulkava, R., Haltia, M., Kainulainen, K., Vuorio, A., Verkkoniemi, A., Niinistö, L., Halonen, P., & Kontula, K. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331902 · Cited by 493
PET imaging of amyloid in Alzheimer's disease
Nordberg, A. K. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00853-1 · Cited by 462
Decreases in regional cerebral blood flow with normal aging
Martin, A. J., Friston, K. J., Colebatch, J. G., & Frackowiak, R. S. J. (1991) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1991.121 · Cited by 393

Show all 38 references

Research works printed but not linked: 1

Grundman M Black R. Clinical trials of bapineuzumab a beta-amyloid-targeted immunotherapy in patients with mild-to-moderate Alzheimer’s disease. In: International Conference on Alzheimer’s Disease (ICAD)

Sorted by citations

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Clinical Neurology and Epidemiology of the Major Neurodegenerative DiseasesPreprint
Erkkinen, M. G., Kim, M., & Geschwind, M. D. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033118 · Cited by 1,231
Brain Imaging in Alzheimer Disease
Johnson, K. A., Fox, N. C., Sperling, R. A., & Klunk, W. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006213 · Cited by 875
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study
Barthel, H., Gertz, H., Dresel, S. H. J., Peters, O., Bartenstein, P., Büerger, K., Hiemeyer, F. J., Wittemer‐Rump, S., Seibyl, J. P., Reininger, C. B., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70077-1 · Cited by 600
The use of PET in Alzheimer disease
Nordberg, A. K., Rinne, J. O., Kadir, A., & Långström, B. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.217 · Cited by 467
APOE4 Allele Disrupts Resting State fMRI Connectivity in the Absence of Amyloid Plaques or Decreased CSF Aβ42
Sheline, Y. I., Morris, J. C., Snyder, A. Z., Price, J. L., Yan, Z., D’Angelo, G., Liu, C., Dixit, S., Benzinger, T. L. S., Fagan, A. M., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.3987-10.2010 · Cited by 444
Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden
Drzezga, A. E., Becker, J. A., Dijk, K. R. A. V., Sreenivasan, A., Talukdar, T., Sullivan, C., Schultz, A. P., Sepulcre, J., Putcha, D., Greve, D. N., et al. (2011) · Brain · doi:10.1093/brain/awr066 · Cited by 385
Self-citation
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia
Ewers, M., Sperling, R. A., Klunk, W. E., Weiner, M. W., & Hampel, H. J. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.05.005 · Cited by 360
Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele
van der Flier, W. M., Pijnenburg, Y. A. L., Fox, N. C., & Scheltens, P. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70306-9 · Cited by 321
PET/MRI for Neurologic Applications
Catana, C., Drzezga, A. E., Heiss, W., & Rosen, B. R. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.105346 · Cited by 292
Self-citation
Changing perspectives regarding late-life dementia
Fotuhi, M., Hachinski, V., & Whitehouse, P. J. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.175 · Cited by 291
Increased metabolic vulnerability in early-onset Alzheimer’s disease is not related to amyloid burden
Rabinovici, G. D., Furst, A. J., Alkalay, A., Racine, C. A., O’Neil, J. P., Janabi, M., Baker, S. L., Agarwal, N., Bonasera, S. J., Mormino, E. C., et al. (2010) · Brain · doi:10.1093/brain/awp326 · Cited by 289
APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease
Youmans, K. L., Tai, L. M., Nwabuisi-Heath, E., Jungbauer, L., Kanekiyo, T., Gan, M., Kim, J., Eimer, W. A., Estus, S., Rebeck, G. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.407957 · Cited by 268
Mild cognitive impairment: pathology and mechanisms
Mufson, E. J., Binder, L. I., Counts, S., DeKosky, S. T., deToledo‐Morrell, L., Ginsberg, S. D., Ikonomović, M. D., Perez, S. E., & Scheff, S. W. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0884-1 · Cited by 268
Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional–executive network function in Alzheimer’s disease
Wolk, D. A., Dickerson, B. C., Initiative, T. A. D. N., Weiner, M., Aiello, M., Aisen, P., Albert, M. S., Alexander, G., Anderson, H. S., Anderson, K., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001412107 · Cited by 248
Apolipoprotein E, gender, and Alzheimer’s disease: an overlooked, but potent and promising interaction
Ungar, L., Altmann, A., & Greicius, M. D. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9272-x · Cited by 246
Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing
Brown, B. M., Peiffer, J. J., Taddei, K., Lui, J. K., Laws, S. M., Gupta, V. B., Taddei, T., Ward, V. K., Rodrigues, M. A., Burnham, S., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.107 · Cited by 235
Beta‐amyloid deposition and the aging brain
Rodrigue, K. M., Kennedy, K. M., & Park, D. C. (2009) · Neuropsychology Review · doi:10.1007/s11065-009-9118-x · Cited by 230
Clinical Validation of 18 F-AZD4694, an Amyloid-β–Specific PET Radioligand
Cselényi, Z., Eriksdotter, M., Forsberg, A., Halldin, C., Julin, P., Schou, M., Johnström, P., Varnäs, K., Svensson, S., & Farde, L. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.094029 · Cited by 225
APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review
Emrani, S., Arain, H. A., DeMarshall, C. A., & Nuriel, T. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00712-4 · Cited by 207
Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition
Rodriguez, G. A., Tai, L. M., LaDu, M. J., & Rebeck, G. W. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-111 · Cited by 193
Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo.
Rabinovici, G. D., & Jagust, W. J. (2009) · PubMed Central · doi:10.3233/ben-2009-0232 · Cited by 194
Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer’s disease
Cummings, J. L., Zhong, K., Kinney, J. W., Heaney, C., Moll-Tudla, J., Joshi, A., Pontecorvo, M., Devous, M., Tang, A., & Bena, J. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0173-2 · Cited by 190
A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease
Nordberg, A., Carter, S. F., Rinne, J., Drzezga, A., Brooks, D. J., Vandenberghe, R., Perani, D., Forsberg, A., Långström, B., Scheinin, N., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2237-2 · Cited by 186
Self-citation
APOE ε2 is associated with milder clinical and pathological Alzheimer disease
Serrano‐Pozo, A., Qian, J., Monsell, S. E., Betensky, R. A., & Hyman, B. T. (2015) · Annals of Neurology · doi:10.1002/ana.24369 · Cited by 176
PET amyloid-beta imaging in preclinical Alzheimer's disease
Vlassenko, A. G., Benzinger, T. L. S., & Morris, J. C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.005 · Cited by 188
Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology
Portelius, E., Olsson, B., Höglund, K., Cullen, N. C., Kvartsberg, H., Andréasson, U., Zetterberg, H., Sandelius, Å., Shaw, L. M. J., Lee, V. M. ‐., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1851-x · Cited by 171
Levels of Soluble Apolipoprotein E/Amyloid-β (Aβ) Complex Are Reduced and Oligomeric Aβ Increased with APOE4 and Alzheimer Disease in a Transgenic Mouse Model and Human Samples*
Tai, L. M., Bilousova, T., Jungbauer, L., Roeske, S. K., Youmans, K. L., Yu, C., Poon, W. W., Cornwell, L. B., Miller, C. A., Vinters, H. V., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.442103 · Cited by 165
Noninvasive brain stimulation in Alzheimer's disease: Systematic review and perspectives for the future
Freitas, C., Mondragón-Llorca, H., & Pascual‐Leone, Á. (2011) · Experimental Gerontology · doi:10.1016/j.exger.2011.04.001 · Cited by 170
Biomarkers for dementia and mild cognitive impairment in Parkinson's disease
Delgado‐Alvarado, M., Gago, B., Navalpotro‐Gómez, I., Jiménez‐Urbieta, H., & Rodríguez-Oroz, M. C. (2016) · Movement Disorders · doi:10.1002/mds.26662 · Cited by 166
Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype
Mishra, S., Blazey, T. M., Holtzman, D. M., Cruchaga, C., Su, Y., Morris, J. C., Benzinger, T. L. S., & Gordon, B. A. (2018) · Brain · doi:10.1093/brain/awy103 · Cited by 151
Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease
Kadir, A., Almkvist, O., Forsberg, A., Wall, A. E., Engler, H., Långström, B., & Nordberg, A. K. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.06.015 · Cited by 161
Epigenetics in Alzheimer’s Disease: Perspective of DNA Methylation
Qazi, T. J., Quan, Z., Mir, A., & Qing, H. (2018) · Molecular Neurobiology · doi:10.1007/s12035-016-0357-6 · Cited by 153
APOE Genotype and Neuroimaging Markers of Alzheimer’s Disease: Systematic Review and Meta-Analysis
Liu, Y., Yu, J.-T., Wang, H.-F., Han, P.-R., Tan, C.-C., Wang, C., Meng, X.-F., Risacher, S. L., Saykin, A. J., & Tan, L. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307719 · Cited by 152
Oscillatory hyperactivity and hyperconnectivity in young APOE-ɛ4 carriers and hypoconnectivity in Alzheimer’s disease
Koelewijn, L., Lancaster, T. M., Linden, D. E. J., Dima, D. C., Routley, B. C., Magazzini, L., Barawi, K., Brindley, L. M., Adams, R., Tansey, K. E., et al. (2019) · eLife · doi:10.7554/elife.36011 · Cited by 151
Invited Review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer's disease
Tzioras, M., Davies, C., Newman, A., Jackson, R., & Spires‐Jones, T. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12529 · Cited by 147
The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI)
Risacher, S. L. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00011 · Cited by 151
White matter hyperintensities predict amyloid increase in Alzheimer's disease
Grimmer, T., Faust, M., Auer, F., Alexopoulos, P., Förstl, H., Henriksen, G., Perneczky, R., Sorg, C., Yousefi, B. H., Drzezga, A. E., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.01.016 · Cited by 146
Self-citation
Epigenetic mechanisms in Alzheimer's disease: Implications for pathogenesis and therapy
Wang, J., Yu, J., Tan, M., Jiang, T., & Tan, L. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.05.003 · Cited by 140
Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging
Lui, J. K., Laws, S. M., Li, Q., Villemagne, V. L., Ames, D. J., Brown, B. M., Bush, A. I., Ruyck, K. D., Dromey, J. R., Ellis, K. A., et al. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-090249 · Cited by 136
Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer’s disease
Baek, M. S., Cho, H., Lee, H. S., Lee, J., Ryu, Y. H., & Lyoo, C. H. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00710-6 · Cited by 137
Cerebral amyloid PET imaging in Alzheimer’s disease
Jack, C. R., Barrio, J. R., & Kepe, V. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1185-7 · Cited by 137
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia
Klunk, W. E. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.006 · Cited by 131
Mapping the Alzheimer’s Brain with Connectomics
Xie, T., & Yong He, A. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00077 · Cited by 129
Dietary Omega 3 Polyunsaturated Fatty Acids and Alzheimers Disease: Interaction with Apolipoprotein E Genotype
Barberger‐Gateau, P., Samieri, C., Féart, C., & Plourde, M. (2011) · Current Alzheimer Research · doi:10.2174/156720511796391926 · Cited by 133
Biomarkers in Alzheimer's disease drug development
Cummings, J. L. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.06.004 · Cited by 122
Diagnostic accuracy of 18F-FDG and 11C-PIB-PET for prediction of short-term conversion to Alzheimer’s disease in subjects with mild cognitive impairment
Zhang, S., Han, D., Tan, X., Feng, J., Guo, Y., & Ding, Y. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02845.x · Cited by 123
Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay
Förster, S., Grimmer, T., Miederer, I., Henriksen, G., Yousefi, B. H., Graner, P., Wester, H.-J., Förstl, H., Kurz, A., Dickerson, B. C., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.023 · Cited by 119
Self-citation
Amyloid PET Imaging in Lewy Body Disorders
Donaghy, P. C., Thomas, A. J., & O'Brien, J. T. (2013) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.03.001 · Cited by 118
Soluble apoE/Aβ complex: mechanism and therapeutic target for APOE4-induced AD risk
Tai, L. M., Mehra, S., Shete, V., Estus, S., Rebeck, G. W., Bu, G., & LaDu, M. J. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-2 · Cited by 116
Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia
Ossenkoppele, R., van der Flier, W. M., Zwan, M. D., Adriaanse, S. F., Boellaard, R., Windhorst, A. D., Barkhof, F., Lammertsma, A. A., Scheltens, P., & van Berckel, B. N. M. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0889 · Cited by 112
Pittsburgh Compound B (11C-PIB) and Fluorodeoxyglucose (18 F-FDG) PET in Patients With Alzheimer Disease, Mild Cognitive Impairment, and Healthy Controls
Devanand, D. P., Mikhno, A., Pelton, G. H., Cuasay, K., Pradhaban, G., Kumar, J. S. D., Upton, N., Lai, R. Y. K., Gunn, R. N., Libri, V., et al. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710363715 · Cited by 109
Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ε4 Genotype in Alzheimer's Disease
Grimmer, T., Tholen, S., Yousefi, B. H., Alexopoulos, P., Förschler, A., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Perneczky, R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.013 · Cited by 105
Self-citation
The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease
Leoni, V. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.088 · Cited by 102
In vivo assessment of amyloid‐β deposition in nondemented very elderly subjects
Mathis, C. A., Kuller, L. H., Klunk, W. E., Snitz, B. E., Price, J. C., Weissfeld, L. A., Rosario, B. L., Lopresti, B. J., Saxton, J. A., Aizenstein, H. J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23797 · Cited by 98
High-Density Lipoproteins and Cerebrovascular Integrity in Alzheimer’s Disease
Stukas, S. K., Robert, J., & Wellington, C. L. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.003 · Cited by 101
Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls
Barthel, H., Luthardt, J., Becker, G., Patt, M., Hammerstein, E., Hartwig, K., Eggers, B., Sattler, B., Schildan, A., Hesse, S., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1821-1 · Cited by 101
Depression and Alzheimer's Disease: Is Stress the Initiating Factor in a Common Neuropathological Cascade?
Aznar, S., & Knudsen, G. M. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100390 · Cited by 98
Influence of brain-derived neurotrophic-factor and apolipoprotein E genetic variants on hippocampal volume and memory performance in healthy young adults
Richter‐Schmidinger, T., Alexopoulos, P., Horn, M., Maus, S., Reichel, M., Rhein, C., Lewczuk, P., Sidiropoulos, C., Kneib, T., Perneczky, R., et al. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0539-8 · Cited by 97
Self-citation
Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study
Mattsson, N., Ossenkoppele, R., Smith, R. A., Strandberg, O. T., Ohlsson, T. G., Jögi, J., Palmqvist, S., Stomrud, E., & Hansson, O. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0403-x · Cited by 90
Apolipoprotein E ε4 modulates functional brain connectome in A lzheimer's disease
Wang, J., Wang, X., He, Y., Yu, X., Wang, H., & He, Y. (2015) · Human Brain Mapping · doi:10.1002/hbm.22740 · Cited by 87
The benefit of docosahexaenoic acid for the adult brain in aging and dementia
Salem, N., Vandal, M., & Calon, F. (2014) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2014.10.003 · Cited by 86
Amyloid load in nondemented brains correlates with APOE e4
Caselli, R. J., Walker, D. G., Sue, L. I., Sabbagh, M. N., & Beach, T. G. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.02.016 · Cited by 85
The Contribution of Genetic Factors to Cognitive Impairment and Dementia: Apolipoprotein E Gene, Gene Interactions, and Polygenic Risk
Fan, J., Tao, W., Li, X., Li, H., Zhang, J., Wei, D., Chen, Y., & Zhang, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051177 · Cited by 87
Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a ‘European ADNI study’
Galluzzi, S., Marizzoni, M., Babiloni, C., Albani, D., Antelmi, L., Bagnoli, C., David Bartrés-faz, A., Cordone, S., Didic, M., Farotti, L., et al. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12482 · Cited by 76
Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework
Chiotis, K., Saint‐Aubert, L., Boccardi, M., Gietl, A. F., Picco, A., Varrone, A., Garibotto, V., Herholz, K., Nobili, F. M., Nordberg, A. K., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.07.012 · Cited by 75
Genetic study of multimodal imaging Alzheimer’s disease progression score implicates novel loci
Scelsi, M. A., Khan, R. R., Lorenzi, M., Christopher, L., Greicius, M. D., Schott, J. M., Ourselin, S., & Altmann, A. (2018) · Brain · doi:10.1093/brain/awy141 · Cited by 73
Influence of apolipoprotein E ɛ4 on rates of cognitive and functional decline in mild cognitive impairment
Whitehair, D. C., Sherzai, A., Emond, J. A., Raman, R., Aisen, P. S. S., Petersen, R. C., Fleisher, A., & Study, A. D. C. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.12.003 · Cited by 73
Dissecting the Gene Dose-Effects of the APOE ε4 and ε2 Alleles on Hippocampal Volumes in Aging and Alzheimer’s Disease
Hostage, C. A., Choudhury, K. R., Doraiswamy, P. M., Petrella, J. R., & Initiative, A. D. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054483 · Cited by 71
Prevalence of Neuropsychiatric Symptoms in Young-Onset Compared to Late-Onset Alzheimer’s Disease – Part 1: Findings of the Two-Year Longitudinal NeedYD-Study
van Vliet, D., de Vugt, M. E., Aalten, P., Bakker, C., Pijnenburg, Y. A. L., Vernooij-Dassen, M. J. F. J., Koopmans, R. T. C. M., & Verhey, F. R. J. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000342824 · Cited by 70
The Association−Dissociation Behavior of the ApoE Proteins: Kinetic and Equilibrium Studies
Garai, K., & Frieden, C. (2010) · Biochemistry · doi:10.1021/bi101407m · Cited by 67
Modifiable, Non-Modifiable, and Clinical Factors Associated with Progression of Alzheimer’s Disease
Loeffler, D. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201182 · Cited by 71
Apolipoprotein E and Gray Matter Volume Loss in Patients with Mild Cognitive Impairment and Alzheimer Disease
Spampinato, M. V., Rumboldt, Z., Hosker, R. J., Mintzer, J. E., & Initiative, A. D. N. (2010) · Radiology · doi:10.1148/radiol.10100307 · Cited by 68
Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans
Rullmann, M., Dukart, J., Hoffmann, K., Luthardt, J., Tiepolt, S., Patt, M., Gertz, H., Schroeter, M. L., Seibyl, J. P., Schulz‐Schaeffer, W., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.161893 · Cited by 66
APOE ε4 Is Associated with Disproportionate Progressive Hippocampal Atrophy in AD
Manning, E. N., Barnes, J., Cash, D. M., Bartlett, J. W., Leung, K. K., Sebastien Ourselin, A., Fox, N. C., & Initiative, A. D. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097608 · Cited by 64
Evidence for altered insulin receptor signaling in Alzheimer's disease
Griffith, C. M., Eid, T., Rose, G. M., & Patrylo, P. R. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.008 · Cited by 64
Neuroimaging Measures as Endophenotypes in Alzheimer′s Disease
Braskie, M. N., Ringman, J. M., & Thompson, P. M. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/490140 · Cited by 62
Advances and perspectives from genetic research: development of biological markers in Alzheimer’s disease
Zetzsche, T., Rujescu, D., Hardy, J., & Hampel, H. J. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.48 · Cited by 63
Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients
Lehmann, M., Ghosh, P., Madison, C. A., Karydas, A., Coppola, G., O’Neil, J. P., Huang, Y., Miller, B. L., Jagust, W., & Rabinovici, G. D. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305858 · Cited by 61
APOE ε4-TOMM40 ‘523 haplotypes and the risk of Alzheimer’s disease in older Caucasian and African Americans
Yu, L., Lutz, M. W., Wilson, R. S., Burns, D. K., Roses, A. D., Saunders, A. M., Yang, J., Gaiteri, C., Jager, P. L. D., Barnes, L. L., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180356 · Cited by 61
White matter microstructure is altered in cognitively normal middle-aged APOE-ε4 homozygotes
Study, F. T. A., Operto, G., Cacciaglia, R., Grau‐Rivera, O., Falcón, C., Brugulat‐Serrat, A., Ródenas, P., Ramos, R., Morán, S., Esteller, M., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0375-x · Cited by 61
Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities
Söderberg, L., Johannesson, M., Gkanatsiou, E., Nygren, P., Fritz, N., Zachrisson, O., Rachalski, A., Svensson, A.-S., Button, E. B., Dentoni, G., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-61691-2 · Cited by 62
Dissociation of Apolipoprotein E Oligomers to Monomer Is Required for High-Affinity Binding to Phospholipid Vesicles
Garai, K., Baban, B., & Frieden, C. (2011) · Biochemistry · doi:10.1021/bi1020106 · Cited by 57
Awareness and Its Association With Affective Symptoms in Young-onset and Late-onset Alzheimer Disease
van Vliet, D., de Vugt, M. E., Köhler, S., Aalten, P., Bakker, C., Pijnenburg, Y. A. L., Vernooij-Dassen, M. J. F. J., Koopmans, R. T. C. M., & Verhey, F. R. J. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31826cffa5 · Cited by 55
Recent insights into the molecular genetics of dementia
Rademakers, R., & Rovelet‐Lecrux, A. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.05.005 · Cited by 56
Amyloid pathway-based candidate gene analysis of [11C]PiB-PET in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort
Swaminathan, S., Shen, L., Risacher, S. L., Yoder, K. K., West, J. D., Kim, S., Nho, K. T., Foroud, T., Inlow, M. H., Potkin, S. G., et al. (2011) · Brain Imaging and Behavior · doi:10.1007/s11682-011-9136-1 · Cited by 54
Genotator: A disease-agnostic tool for genetic annotation of disease
Wall, D. P., Perotte, R., Tong, M. Y., Jung, J.-Y., Fusaro, V. A., DeLuca, T. F., & Tonellato, P. J. (2010) · BMC Medical Genomics · doi:10.1186/1755-8794-3-50 · Cited by 54
APOE‐ε4 associates with hippocampal volume, learning, and memory across the spectrum of Alzheimer's disease and dementia with Lewy bodies
Saeed, U., Mirza, S. S., MacIntosh, B. J., Herrmann, N., Keith, J., Ramirez, J., Nestor, S. M., Yu, Q., Knight, J., Swardfager, W., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.04.005 · Cited by 48
Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer’s Disease Spectrum
Initiative, A. D. N., Liu, Y., Tan, L., Wang, H.-F., Liu, Y., Hao, X., Tan, C., Jiang, T., Liu, B., Zhang, D., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9388-7 · Cited by 54
Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth
Murphy, K. R., Landau, S. M., Choudhury, K. R., Hostage, C. A., Shpanskaya, K. S., Sair, H. I., Petrella, J. R., Wong, T. Z., & Doraiswamy, P. M. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.04.048 · Cited by 50
Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease
Kline, A. D. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt135 · Cited by 53
The potential applications of Apolipoprotein E in personalized medicine
Villeneuve, S., Brisson, D., Marchant, N. L., & Gaudet, D. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00154 · Cited by 50
Brain insulin signalling, glucose metabolism and females' reproductive aging: A dangerous triad in Alzheimer's disease
Duarte, A. I., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.044 · Cited by 49
Protective effects of APOE e2 against disease progression in subcortical vascular mild cognitive impairment patients: A three-year longitudinal study
Kim, Y. J., Seo, S. W., Park, S. B., Yang, J., Lee, J. S., Lee, J., Jang, Y. K., Kim, S. T., Lee, K. H., Lee, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02046-y · Cited by 44
Meta-analytic Comparison Between PIB-PET and FDG-PET Results in Alzheimer’s Disease and MCI
He, W., Liu, D.-H., Radua, J., Li, G., Han, B.-J., & Sun, Z.-G. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0138-7 · Cited by 50
Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease
Förster, S., Yousefi, B. H., Wester, H.-J., Klupp, E., Rominger, A., Förstl, H., Kurz, A., Grimmer, T., & Drzezga, A. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2230-9 · Cited by 45
Self-citation
No Differences in Hippocampal Volume between Carriers and Non-Carriers of the ApoE ε4 and ε2 Alleles in Young Healthy Adolescents
Khan, W., Giampietro, V., Ginestet, C. E., Dell’Acqua, F., Bouls, D., Newhouse, S., Dobson, R., Banaschewski, T., Barker, G. J., Bokde, A. L. W., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131841 · Cited by 44
Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer’s disease dementia
Initiative, A. D. N., Arbizu, J., Prieto, E., Martínez‐Lage, P., Martí-Climent, J. M., García‐Granero, M., Lamet, I., Pástor, P., Riverol, M., Gómez‐Isla, T., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2458-z · Cited by 47
Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid-β Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints
Chiesa, P. A., Cavedo, E., Grothe, M. J., Houot, M., Teipel, S. J., Potier, M., Habert, M., Lista, S., Dubois, B., Hampel, H. J., et al. (2018) · Radiology · doi:10.1148/radiol.2018180268 · Cited by 40

Authors: Drzezga, A., Grimmer, T., Henriksen, G., Mühlau, M., Perneczky, R., Miederer, I., Praus, C., Sorg, C., Wohlschläger, A., Riemenschneider, M., Wester, H. J., Foerstl, H., Schwaiger, M., & Kurz, A.
Affiliations: Technical University of Munich (DE)
From the Departments of Nuclear Medicine (A.D., G.H., I.M., C.P., A.W., H.J.W., M.S.), Psychiatry and Psychotherapy (T.G., R.P., C.S., M.R., H.F., A.K.), Neurology (M.M.), and Neuroradiology (A.W.), Technische Universität München, Munich, Germany.
ORCID: Drzezga, A.
Grimmer, T.
Perneczky, R.
Miederer, I.
Sorg, C.
Riemenschneider, M.
Schwaiger, M.
Kurz, A.
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2009-04-28
Volume: 72
Issue: 17
Pages: 1487-1494
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.0b013e3181a2e8d0
OpenAlex: W2050255138
Cited by: 248
References: 38
Citations by year: 2026: 1 · 2025: 5 · 2024: 7 · 2023: 4 · 2022: 16 · 2021: 6 · 2020: 8 · 2019: 9 · 2018: 17 · 2017: 13 · 2016: 16 · 2015: 18 · 2014: 22 · 2013: 15 · 2012: 25
FWCI: 18.70
Type: journal article
Language: en
Open access: closed
Locations: Neurology (publishedVersion)
PubMed (publishedVersion)
mediaTUM (Technical University of Munich) (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: APOE ε4, Alzheimer's disease, amyloid plaques, gray matter atrophy, 11C-PiB PET, amyloid imaging, genetic risk factors, temporoparietal cortex, partial volume correction
MeSH terms: Aged, Aged, 80 and over, Alzheimer Disease, Aniline Compounds, Apolipoproteins E, Brain, Carbon Radioisotopes, DNA Mutational Analysis, Female, Gene Frequency, Genetic Testing, Genotype, Humans, Male, Middle Aged, Polymorphism, Genetic, Risk Factors, Thiazoles, Amyloid beta-Peptides, Genetic Predisposition to Disease, Positron-Emission Tomography, Benzothiazoles, Apolipoprotein E4, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks